Achieve Life Sciences (ACHV) Revenue & Revenue Breakdown
Achieve Life Sciences Revenue Highlights
00
Achieve Life Sciences Revenue by Period
Achieve Life Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $5.06M | -72.13% |
| 2015-12-31 | $18.16M | -33.03% |
| 2014-12-31 | $27.12M | -9.26% |
| 2013-12-31 | $29.88M | 48.70% |
| 2012-12-31 | $20.09M | 265.63% |
| 2011-12-31 | $5.50M | -59.64% |
| 2010-12-31 | $13.62M | -46.69% |
| 2009-12-31 | $25.54M | 26.86% |
| 2008-12-31 | $20.13M | 0.00% |
| 2007-12-31 | $20.13M | -10.10% |
| 2006-12-31 | $22.39M | 171.27% |
| 2005-12-31 | $8.25M | -96.88% |
| 2004-12-31 | $264.96M | 1059748.00% |
| 2003-12-31 | $25.00K | - |
| 2002-12-31 | $25.00K | -99.71% |
| 2001-12-31 | $8.75M | 2042.11% |
| 2000-12-31 | $408.41K | -96.62% |
| 1999-12-31 | $12.10M | 137.25% |
| 1998-12-31 | $5.10M | -73.02% |
| 1997-12-31 | $18.90M | 13.86% |
| 1996-12-31 | $16.60M | 268.89% |
| 1995-12-31 | $4.50M | 309.09% |
| 1994-12-31 | $1.10M | - |
Achieve Life Sciences generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Achieve Life Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $228.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $2.12M | -27.82% |
| 2016-03-31 | $2.94M | -51.20% |
| 2015-12-31 | $6.02M | -10.58% |
| 2015-09-30 | $6.74M | 67.38% |
| 2015-06-30 | $4.03M | 192.94% |
| 2015-03-31 | $1.37M | -75.69% |
| 2014-12-31 | $5.65M | 17.70% |
| 2014-09-30 | $4.80M | -2.56% |
| 2014-06-30 | $4.93M | -57.98% |
| 2014-03-31 | $11.73M | 36.34% |
| 2013-12-31 | $8.60M | -12.76% |
| 2013-09-30 | $9.86M | 55.55% |
| 2013-06-30 | $6.34M | 24.90% |
| 2013-03-31 | $5.08M | -48.10% |
| 2012-12-31 | $9.78M | 48.86% |
| 2012-09-30 | $6.57M | 170.48% |
| 2012-06-30 | $2.43M | 84.57% |
| 2012-03-31 | $1.32M | 6.47% |
| 2011-12-31 | $1.24M | 5.28% |
| 2011-09-30 | $1.17M | -37.78% |
| 2011-06-30 | $1.89M | 57.38% |
| 2011-03-31 | $1.20M | -48.63% |
| 2010-12-31 | $2.33M | -52.18% |
| 2010-09-30 | $4.88M | 186.95% |
| 2010-06-30 | $1.70M | -63.81% |
| 2010-03-31 | $4.70M | -81.60% |
| 2009-12-31 | $25.54M | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | -100.00% |
| 2007-12-31 | $7.73M | - |
Achieve Life Sciences generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Achieve Life Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TRDA | Entrada Therapeutics | $210.78M | $1.61M |
| VNDA | Vanda Pharmaceuticals | $198.77M | $56.26M |
| ARCT | Arcturus Therapeutics | $152.31M | $17.15M |
| VYGR | Voyager Therapeutics | $80.00M | $13.37M |
| CAPR | Capricor Therapeutics | $22.27M | - |
| ALLO | Allogene Therapeutics | $22.00K | - |
| IMRX | Immuneering | - | - |
| HUMA | Humacyte | - | $753.00K |
| SGMT | Sagimet Biosciences | - | - |
| ACHV | Achieve Life Sciences | - | - |
| AVIR | Atea Pharmaceuticals | - | - |